

Discloser Identifier: 489633

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Self
Recipient Name: Bernstein Clinical Research LLC Grant / Contract Description: Phase III Clinical Trials Additional Information:		
Recipient Type: Institution Grant / Contract Purpose: Research		
GlaxoSmithKline	Grant / Contract	Self
Recipient Name: Bernstein Clinical Research LLC Grant / Contract Description: Phase III clinical trial Additional Information:		
Recipient Type: Institution Grant / Contract Purpose: Research		
GlaxoSmithKline	Consultant	Self
Category: Consultant Description: consulting on new indication Additional Information:		
Sanofi	Grant / Contract	Self
Recipient Name: Bernstein Clinical Research LLC Grant / Contract Description: Clinical Trials Additional Information:		
Recipient Type: Institution Grant / Contract Purpose: Research		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Nicholas Bird

Discloser 1195433
Identifier:

Disclosure 24-06673
Purpose:

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Employment	Self
Title: Director, Biostatistics Additional Information:		Position Description: Statistician in Respiratory Clinical Statistics at GSK
GlaxoSmithKline	Stock	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 888978

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Other	Self
Category: Other Description: received speaker fees and consulting fees from AstraZeneca and grants from AstraZeneca. Additional Information:		
GlaxoSmithKline	Other	Self
Category: Other Description: Has received speaker fees and consulting fees from GSK; and grants from GSK. Additional Information:		
Novartis Pharma	Other	Self
Category: Other Description: Has received speaker fees and consulting fees from Novartis Additional Information:		
Sanofi	Other	Self
Category: Other Description: Has received speaker fees and consulting fees from Sanofi; and grants from Sanofi. Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Six-Monthly Depemokimab in Severe Asthma With an Eosinophilic Phenotype

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Gustavo De Luiz

Discloser Identifier: 1195430

Disclosure Purpose: 24-06673

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Depemokimab efficacy/safety in patients with asthma on medium/high-dose ICS: The Phase IIIA randomised SWIFT-1/2 studies

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1195432

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Other	Self
Category: Other Description: Clinical trial Astma Additional Information: Principal investigator		
Chiesi Farmaceutici	Other	Self
Category: Other Description: clinical trial asthma Additional Information: principal investigator		
Chiesi Farmaceutici	Other	Self
Category: Other Description: Clinical Trial Asthma Additional Information: Principal investigator		
GlaxoSmithKline, LLC.	Other	Self
Category: Other Description: Medical trials Asthma Additional Information: Principal Investigator		
GlaxoSmithKline, LLC.	Other	Self
Category: Other Description: Clinical Trial Asthma Additional Information: principal investigator		
GlaxoSmithKline, LLC.	Other	Self
Category: Other Description: Clinical Trial Asthma Additional Information: Principal Investigator		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Six-Monthly Depemokimab in Severe Asthma With an Eosinophilic Phenotype

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Peter Howarth

Discloser Identifier: 1195436

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Employment	Self
Title: Global Clinical Scientific Lead Additional Information: Full time employment		Position Description: Scientific evidence generation and support for respiratory biologics
GlaxoSmithKline	Stock	Self
Additional Information:		
GlaxoSmithKline	Stock Option	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 321198

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Consultant	Self
Category: Consultant Description: Personal fees for consulting and DSMB Additional Information:		
Avillion	Consultant	Self
Category: Consultant Description: Consulting Additional Information:		
Genentech	Consultant	Self
Category: Consultant Description: Consultant Additional Information:		
GlaxoSmithKline	Consultant	Self
Category: Consultant Description: Steering Committee Additional Information:		
Pfizer	Data And Safety Monitoring	Self
Category: Data And Safety Monitoring Description: DSMB for Atopic Dermatitis Additional Information:		
Regeneron Pharmaceuticals	Consultant	Self
Category: Consultant Description: Consultant Additional Information:		
SANOFI US SERVICES INC.	Consultant	Self
Category: Consultant Description: Consultant Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



David Jackson

Discloser Identifier: 1059269

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Consultant	Self
Category: Consultant Description: Advisory board and speaker fees Additional Information:		
GlaxoSmithKline	Consultant	Self
Category: Consultant Description: Advisory board and speaker fees Additional Information:		
Sanofi	Consultant	Self
Category: Consultant Description: Advisory board and speaker fees Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Loretta Jacques

Discloser Identifier: 768276

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GSK	Employment	Self
Title: SENIOR CLINICAL DEVELOPMENT DIRECTOR Additional Information:		Position Description: Clinical development lead for anti-IL-5 in asthma
GSK	Stock	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Six-Monthly Depemokimab in Severe Asthma With an Eosinophilic Phenotype

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1195429

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Other	Self
Category: Other Description: Speaking Engagement Additional Information:		
AstraZeneca	Other	Self
Category: Other Description: Scientific Advisory Board Additional Information:		
Chiesi Farmaceutici	Other	Self
Category: Other Description: Scientific Advisory Board Additional Information:		
Chiesi Farmaceutici	Other	Self
Category: Other Description: Speaking Engagement Additional Information:		
GlaxoSmithKline	Other	Self
Category: Other Description: Scientific Advisory Board Additional Information:		
GlaxoSmithKline	Other	Self
Category: Other Description: Clinical Trial (Investigator of the presented trial) Additional Information:		
GlaxoSmithKline	Other	Self
Category: Other Description: Speaking Engagement Additional Information:		
Sanofi Genzyme	Other	Self
Category: Other Description: Speaking Engagement Additional Information:		

Entity	Type	Interest Held By
Sanofi Genzyme	Other	Self
Category: Other Description: Scientific Advisory Board Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 622408

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Consultant	Self
Category: Consultant Description: Advisory boards and speaker fees Additional Information:		
Chiesi Farmaceutici	Grant / Contract	Self
Recipient Name: ID Pavord Grant / Contract Description: For phase 2 study of Timapirant Additional Information:		
Recipient Type: Institution Grant / Contract Purpose: Research		
Chiesi Farmaceutici	Consultant	Self
Category: Consultant Description: Advisory boards and speaker fees Additional Information:		
Circassia Pharmaceuticals Inc	Consultant	Self
Category: Consultant Description: Advisory board and speaker fees Additional Information:		
Fondazione Internazionale Menarini	Consultant	Self
Category: Consultant Description: Advisory board Additional Information:		
Fondazione Internazionale Menarini	Consultant	Self
Category: Consultant Description: Speaker fees Additional Information:		
Genentech	Consultant	Self
Category: Consultant Description: Advisory boards Additional Information:		
GlaxoSmithKline	Consultant	Self
Category: Consultant Description: Advisory boards Additional Information:		

Entity	Type	Interest Held By
Knopp	Consultant	Self
Category: Consultant Description: Advisory board Additional Information:		
Merck	Consultant	Self
Category: Consultant Description: Advisory board Additional Information:		
Novartis	Consultant	Self
Category: Consultant Description: Advisory board and speaker fees Additional Information:		
Regeneron Pharmaceuticals	Consultant	Self
Category: Consultant Description: Advisory boards Additional Information:		
SANOPI PASTEUR BIOLOGICS LLC	Consultant	Self
Category: Consultant Description: Advisory board and speaker fees Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. Are you the corresponding author?

Yes.

- a. Please list the other authors' names here.

David J Jackson, FRCP, PhD1; Michael E Wechsler, MD, MMSc2; Daniel J Jackson, MD3; David Bernstein, FAAAAI, FACAAI, FACP, MD4; Stephanie Korn, MD, PhD5; Paul E Pfeffer, MRCP, PhD6; Gustavo de Luíz Martinez, MD7; Lucyna Dymek, MD, PhD8; Ruchong Chen, MD, PhD9; Junpei Saito, MD, PhD10; Loretta Jacques, PhD11; Nicholas Bird, MSc11; Stein Schalkwijk, PharmD, PhD11; Douglas Smith, BS, MBA12; Peter Howarth, DM13; Ian D Pavord, FMedSci14

Certification

I certify that the information provided in this disclosure is complete and accurate.

Paul Pfeffer

Discloser Identifier: 782523

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Other - Institution
<p>Recipient Name: Barts Health NHS Trust Grant / Contract Description: Educational Grant (Improving Asthma Management in A&E) Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Other - Education</p>		
AstraZeneca	Other	Self
<p>Category: Other Description: Lecture(s) at meeting/webinar with honoraria Additional Information: Honoraria for approximately 3 meetings over preceding 3 years</p>		
AstraZeneca	Other	Self
<p>Category: Other Description: Scientific Advisory Board(s) Additional Information: Approx 12 hours Advisory Board activity over preceding 3 years</p>		
AstraZeneca	Travel	Self
<p>Location(s): European Respiratory Science Conferences 2022 & 2024 Purpose: Conference Attendance Additional Information:</p>		
Chiesi Farmaceutici	Other	Self
<p>Category: Other Description: Lecture(s) at meeting/webinar with honoraria Additional Information: Honoraria for approximately 2 meetings over preceding 2 years</p>		
GlaxoSmithKline	Grant / Contract	Other - Institution
<p>Recipient Name: Queen Mary University of London Grant / Contract Description: Research Grant (Autoantigens in Severe Asthma and EGPA) Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research</p>		
GlaxoSmithKline	Other	Self
<p>Category: Other Description: Lecture(s) at meeting/webinar with honoraria Additional Information: Honoraria for approximately 2 meetings over preceding 3 years</p>		
GlaxoSmithKline	Other	Self

Entity	Type	Interest Held By
Category: Other Description: Scientific Advisory Board(s) Additional Information: Approx 12 hours Advisory Board activity over preceding 3 years		
Sanofi	Other	Self
Category: Other Description: Scientific Advisory Board(s) Additional Information: Approx 6 hours Advisory Board activity over preceding 3 years		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Junpei Saito

Discloser Identifier: 1096723

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Other	Self
Category: Other Description: lecture fees Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1195434

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GSK	Employment	Self
Title: Director Additional Information: full time		Position Description: R&D clinical pharmacology
GSK	Stock	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Douglas Smith

Discloser Identifier: 1195435

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Stock	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Six-monthly Depemokimab in severe asthma with an eosinophilic phenotype (24-06673)

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1195428

Disclosure Purpose: 24-06673

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Allakos Inc	Consultant	Self
Category: Consultant Description: Consultant Additional Information:		
Amgen Inc.	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
areteia	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Arrowhead Pharmaceutical	Consultant	Self
Category: Consultant Description: Consultant Additional Information:		
AstraZeneca	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Avalo Therapeutics	Consultant	Self
Category: Consultant Description: Consultant Additional Information:		
Celldex	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Connect Biopharma	Consultant	Self
Category: Consultant Description: Additional Information:		

Entity	Type	Interest Held By
Eli Lilly	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Equillum	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
GENZYME CORPORATION	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
GlaxoSmithKline	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Incyte Corporation	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Iqvia	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Kinaset	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Kymera Therapeutics	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Merck	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
MyBiometry	Consultant	Self
Category: Consultant Description: consultant Additional Information: stock options		
om pharma	Consultant	Self

Entity	Type	Interest Held By
Category: Consultant Description: consultant Additional Information:		
overtone	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Pharming Healthcare, Inc.	Consultant	Self
Category: Consultant Description: Additional Information:		
phylaxis	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
pulmatrix	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
rapt therapeutics	Consultant	Self
Category: Consultant Description: consultant, investigator Additional Information:		
Recludix Pharma Inc	Consultant	Self
Category: Consultant Description: Additional Information:		
Regeneron Pharmaceuticals	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
SANOFI US SERVICES INC.	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
sentien	Data And Safety Monitoring	Self
Category: Data And Safety Monitoring Description: DSMB member Additional Information:		
Sound Biologics	Consultant	Self

Entity	Type	Interest Held By
Category: Consultant Description: consultant Additional Information:		
tetherex	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Uniquity Bio Inc	Consultant	Self
Category: Consultant Description: Consultant Additional Information:		
Upstream Bio	Consultant	Self
Category: Consultant Description: consultant, options Additional Information:		
Upstream Bio	Stock Option	Self
Additional Information: Medical Advisory Board, ad hoc consulting, Approved by Employer		
verona	Consultant	Self
Category: Consultant Description: consultant Additional Information:		
Zurabio	Consultant	Self
Category: Consultant Description: Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Efficacy and Safety of Six-Monthly Depemokimab Therapy in Severe Asthma

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

